If you have any question, please feel free to email us. We will touch with you as soon as possible.
CAS:141505-33-1
Source:Europe
Qualifications:/CEP/-/-/-
| Name | Levosimendan |
|---|---|
| Chinese name | 左旋西孟旦 |
| Cas Number | 141505-33-1 |
| Source | Europe |
| Qualifications | /CEP/-/-/- |
Levosimendan is the first marketed product in the new generation of cardiac drugs-calcium sensitizers. It is mainly used clinically to treat various acute heart failure symptoms. The drug was developed by the Finnish company Orion and was first marketed in Sweden in October 2000. Levosimendan has been used in European and American countries for more than 10 years. It can improve the symptoms and hemodynamics of decompensated acute heart failure without increasing mortality. Levosimendan, as the first calcium sensitizer recommended by the Chinese Guidelines for the Diagnosis and Treatment of Heart Failure in 2014 and 2018, is an important choice in the treatment of heart failure.
Hot Tags: levosimendan api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Dimethyl Fumarate API, Tavaborol API, Celecoxib API, Paliperidone API, Temozolomide API, Apremilast API
Tel:+86-020-61855200-902
Fax:+86-020-66392525
Email:info@upharm.cn
Address:12th floor, No. 181, Kexue Avenue, Huangpu District, Guangzhou, China
